Hostname: page-component-586b7cd67f-g8jcs Total loading time: 0 Render date: 2024-12-04T19:25:31.409Z Has data issue: false hasContentIssue false
  • English
  • Français

Pharmaceutical lobbying under postcommunism: universal or country-specific methods of securing state drug reimbursement in Poland?

Published online by Cambridge University Press:  08 August 2011

Piotr Ozierański ,
Martin McKee  and
Lawrence King
Piotr Ozierański
Affiliation:
Department of Sociology, University of Cambridge, Free School Lane, Cambridge, UK
Martin McKee
Affiliation:
European Centre on Health of Societies in Transition, London School of Hygiene and Tropical Medicine, 15-17 Tavistock Place, London, UK
Lawrence King*
Affiliation:
Department of Sociology, University of Cambridge, Free School Lane, Cambridge, UK
*
Correspondence to: Dr. Lawrence King, Department of Sociology, University of Cambridge, Free School Lane, Cambridge, CB2 3RQ, UK. Email: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

This paper aims to fill in the gap in research on the effect of pharmaceutical lobbying on drug reimbursement policy, particularly in Poland, a post-communist country. To this end, we conducted in-depth, semi-structured, anonymous, elite interviews in Poland, supplemented by a review of legislation, policy documents, official reports and press articles, as well as observations. Overall, 109 representatives of stakeholders involved in reimbursement policy were interviewed. We identified two key lobbying methods: informal persuasion and third-party endorsements. These methods are coupled with two supplementary ones: lobbying through parliament and ministries, as well as diplomatic pressure. Pharmaceutical lobbying methods in Poland clearly resemble those used in other European countries. What is notable about the Polish case is extensive reliance on informal lobbying and diplomatic pressure.

Type
Articles
Information
Health Economics, Policy and Law , Volume 7 , Issue 2 , 02 March 2012 , pp. 175 - 195
Copyright
Copyright © Cambridge University Press 2011

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Abraham, J. (2002), ‘The pharmaceutical industry as a political player’, The Lancet, 360: 1498–1502.CrossRefGoogle ScholarPubMed
Abraham, J. (2009), ‘Partial progress: governing the pharmaceutical industry and the NHS, 1948–2008’, Journal of Health Politics, Policy and Law, 34: 931–977.CrossRefGoogle ScholarPubMed
Abraham, J. (2010), ‘Pharmaceuticalization of society in context: theoretical, empirical and health dimensions’, Sociology, 44: 603–622.CrossRefGoogle Scholar
Abraham, J.Lewis, G. (2000), Regulating medicines in Europe: competition, expertise and public health, London: Routledge.Google Scholar
American Sociological Association (1999), Code of ethics and policies and procedures of the ASA Committee of Professional Ethics, Washington, DC: American Sociological Association.Google Scholar
Angell, M. (2005), The truth about drug companies. How they deceive us and what to do about it?, New York: Random House.Google Scholar
Baggot, R., Allsop, J.Jones, K. (2005), Speaking for patients and carers. Health consumer groups and the policy process, Basingstoke: Palgrave.CrossRefGoogle Scholar
Berrett, A., Roques, T., Small, M.Smith, R. D. (2006), ‘How much will Herceptin really cost?’, British Medical Journal, 333: 1118.Google Scholar
Buckwell, C. (2008), ‘Should the drug industry work with key opinion leaders? Yes’, British Medical Journal, 336: 1404.CrossRefGoogle ScholarPubMed
Burson-Marsteller, (2010), Acceso a los medicamentos, principal prioridad de la industria farmacéutica, 10 September, http://www.analitica.com/noti-tips/6555712.asp [6 November 2010].Google Scholar
Choukroun, B. (2010), ‘The swine flu epidemic: compared analysis of the epidemic media coverage by French and British media’, Lexis Nexis Analytics, October, http://www.lexisnexisanalytics.com/en/news/grippe-a.html [6 November 2010].Google Scholar
Cohen, D.Carter, P. (2010), ‘Conflicts of interest. WHO and the pandemic flu “conspiracies” ’, British Medical Journal, 340: c2912.CrossRefGoogle ScholarPubMed
Conrad, P. (2007), The Medicalization of Society: On the Transformation of Human Conditions into Treatable Disorders, Baltimore, M.D.: Johns Hopkins University Press.CrossRefGoogle Scholar
Fava, G. A. (2008), ‘Should the drug industry work with key opinion leaders? No’, British Medical Journal, 336: 1405.CrossRefGoogle ScholarPubMed
Ferner, R. E.McDowell, S. E. (2006), ‘How NICE may be outflanked’, British Medical Journal, 332: 1268–1271.CrossRefGoogle ScholarPubMed
García-Sempere, A.Artell, J. J. (2005), ‘Organización, funcionamiento y expectativas de las organizaciones representativas de pacientes. Encuesta a informadores clave’, Gaceta Sanitaria, 19(2): 120–126.CrossRefGoogle Scholar
Geertz, C. (1973), ‘Thick description: toward an interpretive theory of culture’, in C. Geertz (ed.), The Interpretation of Cultures: Selected Essays, New York: Basic Books, 3–30.Google Scholar
Grant, W. (2000), Pressure Groups and British Politics, London: MacMillan.CrossRefGoogle Scholar
Hague, R., Harrop, M. (1992), Comparative government and politics: an introduction (3rd revised edition), Basingstoke: Macmillan.CrossRefGoogle Scholar
Health Committee (2005), The Influence of the Pharmaceutical Industry. Fourth Report of Session 2004–2005, London: Stationery Office.Google Scholar
Hemminki, E., Toiviainen, H. K.Vuorenkoski, L. (2010), ‘Co-operation between patient organisations and the drug industry in Finland’, Social Science and Medicine, 70(8): 1171–1175.CrossRefGoogle ScholarPubMed
Herxheimer, A. (2003), ‘Relationships between the pharmaceutical industry and patients’ organisations’, British Medical Journal, 326: 1208–1210.CrossRefGoogle ScholarPubMed
Hood, C. (2011), The blame game: spin, bureaucracy and self-preservation in government, Princeton, N.J.: Princeton University Press.Google Scholar
IMS Health and Rynek Zdrowia (2010), ‘Polska w czołówce rynków wschodzących w farmacji’. Rynek Zdrowia, 21 April, http://www.rynekzdrowia.pl/Farmacja/Polska-w-czolowce-rynkow-wschodzacych-w-farmacji,17503,6.html [14 September 2010].Google Scholar
Jakubiak, L. (2009a), ‘Podawanie paliwizumabu wcześniakom: nie ma zgodności co do oceny skuteczności’, Rynek Zdrowia, 16 October, http://www.rynekzdrowia.pl/Farmacja/Podawanie-paliwizumabu-wczesniakom-nie-ma-zgodnosci-co-do-oceny-skutecznosci,11816,6.html [15 September 2010].Google Scholar
Jakubiak, L. (2009b), ‘Rynek leków kreuje korupcjogenne zachowania, trzeba więc z tym walczyć’, Rynek Zdrowia, 12 December, http://www.rynekzdrowia.pl/Prawo/Rynek-lekow-kreuje-korupcjogenne-zachowania-trzeba-wiec-z-tym-walczyc,13764,2,1.html [10 November 2010].Google Scholar
Jones, K. (2008), ‘In whose interest? Relationships between health consumer groups and the pharmaceutical industry in the UK’, Sociology of Health and Illness, 30(6): 929–943.CrossRefGoogle ScholarPubMed
Kent, A. (2007), ‘Should patient groups accept money from drug companies? Yes’, British Medical Journal, 334: 934.CrossRefGoogle ScholarPubMed
Kopřivová, H. (2007), ‘Postavení farmaceutických firem v českém zdravotním systemu’, Diploma Thesis. Masarykova univerzita, Brno, http://is.muni.cz/th/76203/esf_m/DP-Helena_Koprivova_FINAL.pdf [6 November 2010].Google Scholar
Kvale, S. (1996), InterViews. An introduction to qualitative research interviewing, London, Thousand Oaks, New Delhi: SAGE Publications.Google Scholar
Łapiński, M. (2005), Walka z sitwą, Warszawa: Offsetowa Drukarnia Wydawnicza.Google Scholar
Ledeneva, A. V. (2006), How Russia really works? The informal practices that shaped Post-Soviet politics and business, Ithaca, NY: Cornell University Press.Google Scholar
Malinowski, B. (2002), Argonauts of the Western Pacific: An account of native enterprise and adventure in The Archipelagoes of Melanesian New Guinea, London and New York: Routledge.CrossRefGoogle Scholar
Meyer, G. (ed.) (2006) Formal institutions and informal politics in Central and Eastern Europe. Hungary, Poland, Russia and Ukraine, Opladen and Farmington Hills: Barbara Budrich Publishers.Google Scholar
Ministerstwo Zdrowia (2004), Polityka lekowa państwa 2004–2008, Warszawa: Ministerstwo Zdrowia.Google Scholar
Ministerstwo Zdrowia (2005), Strategia rozwoju ochrony zdrowia w Polce na lata 2007–13. Dokument przyjęty przez RM w dniu 21 czerwca 2005 r, Warszawa: Ministerstwo Zdrowia.Google Scholar
Mintzes, B. (2007), ‘Should patient groups accept money from drug companies? No.’, British Medical Journal, 334: 935.CrossRefGoogle ScholarPubMed
Money.pl (2007), ‘SN: Deszczyński ma być przeproszony za tekst “Leki za miliony dolarów” ’. Money.pl, 13 April, http://www.money.pl/archiwum/wiadomosci_agencyjne/pap/artykul/sn;deszczynski;ma;byc;przeproszony;za;tekst;leki;za;miliony;dolarow,20,0,235796.html [24 September 2010].Google Scholar
Moynihan, R. (2003), ‘Who pays for the pizza? Redefining the relationships between doctors and drug companies. 1: entanglement’, British Medical Journal, 326: 1189–1192.CrossRefGoogle ScholarPubMed
Moynihan, R. (2008), ‘Key opinion leaders. Independent experts or drug representatives in disguise?’, British Medical Journal, 336: 1402–1403.CrossRefGoogle ScholarPubMed
Moynihan, R., Heath, I.Henry, D. (2003), ‘Selling sickness: the pharmaceutical industry and disease mongering’, British Medical Journal, 324: 886–891.CrossRefGoogle Scholar
Nicoll, A.McKee, M. (2010), ‘Moderate pandemic, not many dead – learning the right lessons in Europe from the 2009 pandemic’, European Journal of Public Health, 20(5): 486–488.CrossRefGoogle Scholar
Najwyższa Izba Kontroli (2004), Informacja o wynikach kontroli funkcjonowania systemu tworzenia wykazu leków refundowanych.Google Scholar
Najwyższa Izba Kontroli (2007), Wystąpienie pokontrolne – Samodzielny Publicznym Szpitalu Klinicznym nr 5 Śląskiego Uniwersytetu Medycznego.Google Scholar
Najwyższa Izba Kontroli (2009), Wystąpienie pokontrolne – Zespół Opieki Zdrowotnej w Końskich (ZOZ).Google Scholar
Narodowy Fundusz Zdrowia (2006), Sprawozdanie z działalności Narodowego Funduszu Zdrowia za 2005 rok, Warszawa: Narodowy Fundusz Zdrowia.Google Scholar
Narodowy Fundusz Zdrowia (2007), Sprawozdanie z działalności Narodowego Funduszu Zdrowia za 2006 rok, Warszawa: Narodowy Fundusz Zdrowia.Google Scholar
Narodowy Fundusz Zdrowia (2008), Sprawozdanie z działalności Narodowego Funduszu Zdrowia za 2007 rok, Warszawa: Narodowy Fundusz Zdrowia.Google Scholar
Narodowy Fundusz Zdrowia (2009), Sprawozdanie z działalności Narodowego Funduszu Zdrowia za 2008 rok, Warszawa: Narodowy Fundusz Zdrowia.Google Scholar
Narodowy Fundusz Zdrowia (2010a), Sprawozdanie z działalności Narodowego Funduszu Zdrowia za 2009 rok, Warszawa: Narodowy Fundusz Zdrowia.Google Scholar
Narodowy Fundusz Zdrowia (2010b), Zmiana planu finansowego Narodowego Funduszu Zdrowia na 2010 r. zatwierdzona przez Ministra Zdrowia w porozumieniu z Ministrem Finansów w dniu 6 lipca 2010 r, Warszawa: Narodowy Fundusz Zdrowia.Google Scholar
OECD (2011), Consumer prices (MEI): consumer prices – annual inflation, http://stats.oecd.org/Index.aspx [22 April 2011].Google Scholar
Oldani, M. J. (2004), ‘Thick prescriptions: toward an interpretation of pharmaceutical sales practices’, Medical Anthropology Quarterly, 18: 325–356.CrossRefGoogle ScholarPubMed
Parliamentary Assembly of the Council of Europe (2010), Report, recommendation and resolution 24/06/2010. The handling of the H1N1 Pandemic: more transparency Needed, Strasbourg: Parliamentary Assembly of the Council of Europe.Google Scholar
Payet, M. (2010), ‘Swine flu experts under the influence of laboratories. Le Parisien explores pharma links to WHO and French government,’ (Translated by Carolyn Dunning) Le Parisien, 26 January, http://www.theflucase.com/index.php?option=com_contentandview=articleandid=2656%3Ale-parisien-explores-pharma-links-to-who-and-french-govenrmentandcatid=1%3Alatest-newsandItemid=64andlang=fr [5 November 2010].Google Scholar
Peräkylä, A. (1997), ‘Reliability and validity in research based on tapes and transcripts’, in D. Silverman (ed.), Qualitative Research. Theory, Methods and Practice, London, Thousand Oaks, New Delhi: Sage Publications, 201–220.Google Scholar
Procedura (2009), Procedura przyjmowania klientów zewnętrznych, Warszawa: Ministerstwo Zdrowia.Google Scholar
Rynek Zdrowia (2010), ‘Coraz dłuższa kolejka chętnych do poprawiania projektu ustawy refundacyjnej’, 18 October, http://www.rynekzdrowia.pl/Farmacja/Coraz-dluzsza-kolejka-chetnych-do-poprawiania-projektu-ustawy-refundacyjnej,102783,6.html [10 November 2010].Google Scholar
Silverman, D. (1993), Interpreting qualitative data. Methods for analysing talk, text and interaction, London: Sage Publications.Google Scholar
Sismondo, S. (2008), ‘How pharmaceutical industry funding affects trial outcomes: causal structures and responses’, Social Science & Medicine, 66: 1909–1914.CrossRefGoogle ScholarPubMed
Solska, J. (2009), ‘Zakładnicy’, Polityka 21 February.Google Scholar
Spielmans, G. I.Parry, P. I. (2010), ‘From evidence-based medicine to marketing-based medicine: evidence from internal industry documents’, Journal of Bioethical Inquiry, 7(1): 13–29.CrossRefGoogle Scholar
Strauss, A. L. (2001), Qualitative analysis for social scientists, Cambridge: Cambridge University Press.Google Scholar
The Lancet (2005), ‘Herceptin and early breast cancer: a moment for caution’, The Lancet, 366(9498): 1673.CrossRefGoogle Scholar
Tiedemann, A. (2009), EU market access teams: new instruments to tackle non-tariff barriers to trade, Bruges: College of Europe.Google Scholar
Traufetter, G. (2009), ‘German government flu expert advising pharma “lobby group” ’, Spiegel Online International, 28 October, http://www.spiegel.de/international/germany/0,1518,657910,00.html [5 November 2010].Google Scholar
Ustawa (2009), Ustawa z dnia 6 listopada 2008 r. o konsultantach w ochronie zdrowia, Dz.U. Dz.U. 2009 nr 52 poz. 419.Google Scholar
Vuorenkoski, L., Toiviainen, H.Hemminki, E. (2003), ‘Drug reimbursement in Finland: the case of explicit prioritising in special categories’, Health Policy, 66(2): 169–177.CrossRefGoogle ScholarPubMed
Wilson, P. M., Booth, A. M., Eastwood, A.Watt, I. S. (2008), Deconstructing media coverage of trastuzumab (Herceptin): an analysis of national newspaper coverage’, Journal of the Royal Society of Medicine, 101(3): 125–132.CrossRefGoogle ScholarPubMed
Zarzycki, T., (2010), ‘Firmy farmaceutyczne muszą dostosować się do zmian prawnych’, Rynek Zdrowia, 23 April, http://www.rynekzdrowia.pl/Farmacja/Firmy-farmaceutyczne-musza-dostosowac-sie-do-zmian-prawnych,17592,6.html [15 June 2010].Google Scholar